INTRODUCTION
Nanotechnology possesses enormous potential to produce products, with novel properties, in various domains, whose importance is expected to get enhanced, in near future. Novel materials and devices resulting from said technology have broad introduction potentiality in all domain including biotechnology, food, and pharmaceutical sector. In pharmaceutical field, introduction of nanotechnology is achieving in devising nanotherapeuticsand nanodevices. Semi-biological nanodevicesare multifunctionaloffering versatile therapeutic services and demonstrating unitary biochemical activities. While amalgamation of imaging and therapeutic function in a single nanodevice can provide prognostic information concurrent with therapeutic intervention 1 .
Presently, pharmaceuticals containing nanotherapeuticsand nanodevicesare under extensive study for improving performance 1 . Ongoing attempt is to present them as disinfectants; biosensor or bio-tracer based diagnostic agent for detecting toxins, pathogens, volatile compounds, and organic components of body fluids; and for monitoring diseases 1 . Besides these they will revolutionise offering of device for site-specific controlled delivery of drug or drug targeting, and presenting of differential device-activity in dissimilar physiological environments, under direction of an external operator / physician [2] [3] [4] [5] [6] . Several nano sized pharmaceuticals were designed for oral delivery of nanotherapeuticmacromolecules but polymeric nanocarriers gaining popularity 7 . They allows paracellular and transcellulartranscytosis of macromolecules and site specific delivery or targeting, and provide desirable biopharmaceutical and pharmacokinetic profile [8] [9] [10] [11] . Their consensus on increasing efficacy, specificity, tolerability and therapeutic index and prognostic on minimising toxicities are available 3, 4, [12] [13] [14] [15] [16] [17] .
Polymeric nanocarriers with diverse functionality were designed using several materials and following various process or technique. They be either a vesicular system (i.e., nanovesicles, encapsulates drug in a cavity of polymeric membrane) or a matrix system (i.e., nanoparticles (NPs), in which drug is physically and uniformly dispersed) 7, 12, 18, 19 . All of these systems have limitations and superiority over others. Choice of system afoot on desired physicochemical properties and targeted therapeutic objective 3, 6, 7 .Biodegradable polymers of natural or synthetic origin used to wider extentwhile nonbiodegradable polymers are in rare use 1, 20 . Table 1 depicts glimpse on IUPAC name and structure of polymers used for developing nanocarriers, while Table 2 presents glimpse on specialism of nanocarriers.
Adsorbing or grafting of molecules on surface of nanocarriers modifies its surface property that in turn modifies interaction with intestinal mucosa. Ligand molecule like antibodies, glycoproteins or peptides confers targeting 9, [22] [23] [24] [25] while that of hydrophilic one,polyethylene glycol (PEG), improves transcytosis 21 .Adsorbing or coating of them with mucoadhesives (viz. chitosan) imparts mucoadhesive property 1, 5 . Diverse methods followed for preparing them, depending on nature of polymer and drug. Use of process involving electrostatic interaction wise option, employ polyelectrolyte complexes and eliminates application of detrimental or aggressive in-process conditions 27, 28 . While method requiring heat, organic solvent, sonication or vigorous agitation is unsuitable for biopharmaceuticals 1, 20 . 4-7, 20, 29, 30 .Chitosan and its derivatives used popularly linked with biocompatible, non-toxic, mucoadhesive, targeting, and tight junctions (TJs) opening property [29] [30] [31] [32] [33] . Its limited solubility at pH > 6.5 being overcome by introducing alkyl groups to amine groups 34 . Polyelectrolyte complexes of 200-400 nm size formed with these 27 . PLA, PLGA, PCL biodegrade through hydrolysis while PCA with esterase. PCL degrade slowly than PLGA, thus suitable for extending delivery 20, 35 . Chitosan used to greater extent while dextran, gelatine and alginate used to lesser extent 1 .
NANOVESICLES
Surfactants and amphiphilic polymers / copolymers form colloidal dispersions of molecular aggregates or vesicles 13, 19, 36 . Lipid-based vesicles are solid-lipid nanocarriers (SLN), micelles, lipid microspheres (lipospheres) and liposomes (LIP) while surfactant based is niosomes 13, 14, 19, 37, 38 . In contrast to NPs, which display a static and stable structure, they form a dynamic structure. These can carry drug in core or on corona and can solubilise poorly soluble drugs and partly protect drug from aqueous environment, thus preferred for poorly soluble drugs 15, 18, 19 .SLN and niosomes are more stable and advantageous comparing LIP, can incorporate hydrophilic and/or hydrophobic drug. They protect incorporated drug from degradation; are biocompatible, safe, and well-tolerated; offer possibility for controlled release and drug targeting; and so on 14, 15, 18, 38 . SLN exhibit beneficial solid state behaviour (crystallinity, polymorphism and thermal behaviour) as consequences of non-spherical particle shape, usually. Crystalline natured lipid core of which contribute additional beneficent features, including altering pharmacokinetics profiles, comparing others 12, 37 .
Copolymer of PLA-PEG, PCL-PEG, or low molecular weight polyester-PEG is cheaper and safe but their use limited by involvement of sophisticated technology and machine, and organic solvents. Lecithin, tween 80, poloxamer 188, span 85, cetylpalmitate, and sodium glycocholate are safe 38 .Amphiphilic copolymers provide enhanced kinetic and thermodynamic stability comparing surfactants 14, 15, 18 .Copolymer of pluronic-polyacrylic acid and poloxamer results pH-sensitive micelles 39, 40 . Derivatives of PEGylated α-tocopherol and tocopherol polyethylene glycol succinate (TPGS), is biocompatible and suitable for delivering both soluble and poorly water soluble drugs 14, 15, 19, 38 .Poloxamer solubilise drugs and enhance drug transport across the intestinal barriers 11, 41 .
SLN formulated by solvent evaporation method or melt dispersion method but latter is advantageous as eliminates use of organic solvents [42] [43] [44] .LIP, lipospheres and niosomes are formed either by simple direct dissolution in water or by dissolving drug and polymer in organic solvents before solvent evaporation or dialysis 19, 36, 45, 46 .
The polymers or copolymers use for micelles should (i) spontaneously self-assemble in water, (ii) enhance drug solubility by several fold (iii) provide high loading efficiency (iv) remain stable in the gastrointestinal (GI) tract, (v) be biocompatible and non toxic and (vi) easy to synthesise in commercial scale (vii) cheap and easily assessable.
After oral administration, nanocarriers degrade with variation of pH levels and presence of enzymes or bile salts. Their composition strongly influences stability in GI tract. Nanocarriers prepared with insoluble polymers neither immediately degrades nor rapidly releases drug.
While that with water-soluble polymers, forming polyelectrolyte one, are more likely to destabilise by pH or ionic strength. Kinetic stability of NPs is better than nanovesicles 7, 13 .
BIODISTRIBUTION OF NANOCARRIERS
ATP-binding cassette (ABC) transporters (like Pglycoprotein (P-gp) and multi-drug resistance-associated proteins expressed by intestinal epithelial membrane) and various solute transporters facilitate absorption of nanocarriers and or drugs. The ABC transporters are ATP dependent thus limits absorption in a dose-dependent, inhibitable and saturable manner and can pump against steep of concentration 41, 47-50 .
Upon crossing mucus the nanocarriers are traversing intestinal epithelium via paracellular pathway and/or transcytosis.
Receptor-mediated transcytosis (internalization through endocytic pathways) is specific to intracellular locations and processes and mediated by enterocytes or M cells 50 . Endocytosis mechanism involves phagocytosis and pinocytosis. Phagocytosis is restricted to M cells and phagocytic immune cells 47, 51 . Pinocytosis occurs by macropinocytosis (a transient process) and micropinocytosis (a constitutive pathway) 5, 41 .
Micropinocytosis involves clathrin-mediated endocytosis (ClME), caveolae-mediated endocytosis (CaME) and clathrin-and caveolae-independent endocytosis. ClME involves either specific receptor-ligand interaction or nonspecific endocytosis. Macropinocytosis and ClME involves fusion with endolysosomes whereas CaME involve direct exocytosis by escaping endolysosomes. CaME involves formation of flask-shaped invaginations, a static structures with a size of 50 to 100 nm, of the plasma membrane in cholesterol and sphingo lipid-rich microdomains 47, 50, 51 .
After absorption, drug and/or drug loaded nanocarriers can be included in cytoplasmic vesicles or diffuse in cytoplasm and be discharged in serosal spaces for gaining access to mesentheric lymph or blood 5, 26, 41, 48 .The size, composition, surface characteristics and architecture of them along with physicochemical properties of polymer (viz. molecular weight, conformation, hydrophobicity, and so on) will monitor their absorption 9, 10, 47 . Water-insoluble polymers forms stable nanocarriers and are more likely absorbed as particles 5 . Polymers forming less stable particles, polyelectrolyte complexes, vesicles or micelles will partly get dissociate and will not completely get absorbed as particle 10, 14, 15, 38 .Nanocarriers taken up by absorptive enterocytes mainly delivered in blood. While those taken up by M cells will transcytosis close to immune cells and are likely be delivered to the gut-associated lymphoid tissue and lymphoid cells 5, 9, 10 . Drugs encapsulated in NPs are not likely to be substrate of efflux pump while hydrophobic drugs forming core of micelles are more likely to be transported by efflux pumps 5, 10, 11 .Delivery mechanism of macromolecule through oral route is presented with Figure- 
BIOAVAILABILITY IMPROVEMENT TECHNIQUES
In paracellular route junction-proteins present at tight or adherens junction restrains passage of macromolecules or aggregates with size more than one nm. Consensus on nanocarriers is generally they do not transverse intestinal barrier by paracellular route 22, 26, 48 . While in transcellular route major limiting factor is intestinal mucosa which requires redresses for improving bioavailability of orally delivered macromolecules 5, 8, 16, 22, 41, 47, 50, 52 .
Improvement in delivery of drug, by paracellular way, can be achievable by grafting modulators of junctional proteins on the surface of nanocarriers 5, 22 . These modulators act directly or indirectly on TJ components, proteins or surface receptor resulting reversible opening of membranous barriers 32, 33 . Some modulators disrupt the TJs via activation of protein kinase C and the adherens junctions by chelating calcium 22, 47, 50 . Transcellular translocation of nanocarriers seems influencing by several physicochemical parameters including surface hydrophobicity, polymer nature and particle size. These factors influence their fate within enterocytes or M cells while efflux pumps may strongly reduce extent of net drug uptake 8, 16, 41, 47, 50 . Bioavailability or performance of nanocarriers ought to be improving through protecting drug from detrimental GI tract environment, prolonging their GI-residence time by mucoadhesion, their endocytosis, and permeabilising effect of polymer 1, 5, 8, 39, 47 .
ENDOCYTOSIS
Internalization of nanocarriers through endocytosis pathway depends on physicochemical characteristics and size of the particle and the cell type. Their transport can be enhanced by specifically targeting receptors (mediating endocytosis) through grafting or coating them with ligand, having affinity for receptors 8, 22, 41, 47, 49, 50 .Several nonexhaustive receptors are there whose targeting can be done to increase their transport mediated by intestinal cells, globet cells or M cells 9, 24, 47, 49, 51, 53, 54 .Pattern recognition receptors (PRRs) such as toll-like receptor-4,plateletactivating factor receptor and α5β1 integrinpresent on the surface of M cells considered as important in antigen transcytosis 55 . A few specific ligands of human M cells have been identified 3, 9, 23 . Grafting of these M cell homing peptides (CKSTHPLSC (CKS9), CSKSSDYQC (CSC)) results in targeting of M cells and enhances transport 23, 56, 57 . Nanocarriers mimicking structure of pathogen or having affinity for M cells is suitable for oral immunisation 55 .
Integrins can be targeted with Arg-Gly-Asp (RGD) and aspartic-acid-based ligands. Among these RGD peptides cyclic peptides c(RGDfK) and c(RGDyK), RGD4C, and RGD10 showed high binding affinity and selectivity for integrin 54 .
TARGETING
Many emerging nanocarriers are essentially delivery devices strongly emphasising on control of therapeutic action in time and space 1 .Targeted delivery devices depending on biologic affinity interactions (using vascular address system) and physical/chemical properties (enhanced permeability and retention effect), and pro-drug strategies (devices that are active only at preselected sites of disease) have emerged recent years 3, 6, 9, 16 . Other related modalities are controlling the assembly or activity of devices at particular sites or at particular times in response to a signal provided by an external operator. Such signals are physical (a magnetic field) or biochemical (an enzyme transforming therapeutic to an active form) in nature 32, 49 . Up-regulating expression of some receptors using an appropriate stimulant is another strategy of targeting. Stimulation of these receptors with ligands, lipopolysaccharide or cytokines increases particle uptake by human follicle-associated epithelium cells 5, 8, 9, 56, 57 . Some lectins can result targeting of adhesion molecules present on enterocytes and M cell membranes. Grafting of ligand is particularly attractive for oral vaccine delivery 9, 23, 57 . Adhesive factors (flagellin and invasins) derived from microorganisms, vitamins, and carbohydrates are used as ligands 1, 5, 58, 59, 60 .
Conjugating lectins to nanocarriers increases transport across the intestinal mucosa while grafting them with vitamin B 12 allows targeting to intrinsic factor specific receptor 10, 50, 60, 61 . Targeting of NPs and internalisation of micelles takes place via ClME. Endocytic translocation of small particles (with size 50-100 nm) mediated by enterocytes whilst larger particles mediated by M cells 10, 41, 47, 50, 51 .Chitosan and PLGA nanocarriers enhance transport via ClME 31 . Nanocarriers coated or grafted with ligands like folic acid, albumin and cholesterol, gets internalized by CaME 51 . Targeting of globet cell 53 , peyer's patches (PPs) 45, 56 , dendritic cells (DCs) of PPs 62 done by grafting ligands, having homing property or affinity forthem. Pluronic 85 unimers enter epithelial cells through caveolae-dependent and caveolae-independent pathways 63 . Thiamine-coated NPs captured by PPs 58, 56 .
MUCOADHESION
Prolongation in GI-residence time of nanocarriers will improve efficiency in transversing intestinal epithelium, thereby improving bioavailability 26, 39, 58 . This ought to get improved by decreasing their size below 200 nm, which in turn will diffuse through mucus and circumvent elimination by mucilliary clearance. Mucoadhesion translates to cumulative protein release and absorption 39, 59, 64 .
DISCUSSION AND STRATEGY FOR DEVELOPMENT
Nowadays NBODSM considered as promising alternative to parenteral one. pH sensitive, untargeted, or targeted (with or without grafting of ligand) NBODSM had been exploited in most cases 1, 5, 16, 30, 65 . Future of their marketing remains uncertain due to following facts.
(i) High cost of synthesising polymer, manufacturing nanocarriers and scaling-up, (ii) Improvement of bioavailability to stable and efficient therapeutic level, (iii) High inter-and intra-individual variations in pharmacokinetics of macromolecules, and (iv) Optimizing polymeric composition of them for specific macromolecules.
Selection of nanocarrier remains controversial for delivering macromolecules. Amenability of NPs for modulation in physicochemical and biological behaviour makes them versatile, thus suitable for delivering wide variety of drug with or without target specificity 5 . Micelles considered viable approach for delivering poorly soluble macromolecules comparing cyclodextrins based solid dispersions or lipid-based systems 13, 19, 36, 38 . pH-sensitive micelles minimises initial burst release of macromolecules in stomach but releases them at pH 5, in a molecularly dispersed form 40 . LIP and lipospheres have lower toxicity and higher tolerability, and suitable for poorly soluble macromolecules 45, 46 .SLN, comprises physiological and well-tolerated lipids, offer controlled release and targeting, provide protection against degradation, and is advantageous over other colloidal carriers 12, 42, 44, 66, 67 .
Size of nanocarriers should be essentially within 10-200 nm, to promote diffusion in mucus and uptake by intestinal cells, and to decrease uptake by reticulo-endothelial system (RES) 16 . Surface modification of them with PEG will prevent their uptake by RES and prolong circulation half-life 21, 25 . Imparting mucoadhesion property will prolong their residence time without impeding diffusion in mucus 39, 58, 59 .Their surface charge has to be positive favouring interaction with mucus and cell membrane but be neutral to decrease RES clearance 26, 39, 64 .
The mechanisms of drug absorption from micelles differ from NPs uptake. Nanocarriers should be stable in GI tract while releasing drug at desired site with predetermined rate. They may have targeting potentiality for M cells or immunocompetent cells of GI tract 9, 38, 47, 50 .
Chitosan have ability to cause reversible opening of TJs and have mucoadhesive property 29, 32, 33, 68 .Improvement in paracellular permeability did not increases permeability of endotoxins and lipopolysaccharide thus is safe 69 . Polyelectrolyte complexation of drug with chitosan prevents enzymatic degradation in GI environment 28 . Hydrogel system of alginate, dextran sulphate and poloxamer 188 consisting multilayered NPs of chitosan improves entrapment and gastric retention. Poloxamers improves solubility and transport of drug 8, 41, 48 . Decreasing concentration of Ca 2+ and increasing concentration of poloxamer and albumin results smaller NPs. Reduction in albumin content improves entrapment and gastric retention 10, 11 .
Loss in mucoadhesive and TJopening properties of chitosan at pH 7.4 is improved by derivatisation 29, 33, 34 . Ntrimethylated chitosan (NTC), thiolated chitosan (TC) 68 , N-(2-hydroxyl) propyl-3-trimethyl ammonium chitosan (NTAC) 70 , are important derivatives 29 . These categorised as pH-sensitive polymers used for improving bioavailability alone or in combination with other polymer 4, 71 . PEGylatedchitosan have enhanced permeability and lower toxicity 25 . Gama-polyglutamic acid (γPGA)-NTC based NPs allow absorption of macromolecules throughout the intestinal tract 71, 72 . NTC based NPs involve active transport and electrostatic interaction, which upon conjugation with ligand CKS9, CSC enhances absorption, further, via clathrin-and caveolae-mediated endocytosis 23, 53, 56, 57 .From pHresponsive NPs macromolecules gets absorbed into systemic circulation while carrier retained mainly in oral tract 65, 73 . Some pH-responsive nanocarriers are biodegradable 40 .TC improves mucoadhesion and absorption eliminating toxicity and biocompatibility issue 68 . NTAC exhibit higher cationic charge density, increased mucoadhesion, TJ opening ability and were non-cytotoxic 70 .
NPs of chitosan-γPGA increase their absorption in intestine and sustain release. Their conjugation with CSC results targeting of goblet cells,but with diethylenetriaminepentaaceticacid disruptsTJs 71 . Blending chitosan and γPGA with tripolyphosphate and MgSO 4 result multi-ion-crosslinked NPs, possessing stability over broader pH ranges and improved transporting capability, and more compact one 8, 29 .
Acrylic-based polymers and copolymers like poly(isobutylcyanoacrylate) (PIBCA), poly(acrylic acid) (PAA), poly(alkylcyanoacrylate), PEG grafted methacrylic acid (MAA) or acrylic acid used to get pH sensitive NPs. Copolymerising MAA with PEG dimethacrylate (PG-DMAA) having molecular weights of 400-4000 g/mol results hydrophilic and pH-sensitive poly(PG-DMAA-MAA) NPs 5, 7, 25, 30 .Modification of dextran based NPs through conjugation of its surface with vitamin B 12 results targeting with better transport and higher bioavailability 60 .Thiolatedpoly(acrylic acid) or it's blend with chitosan improves mucoadhesive properties of NPs 68, 74 .
PLGA NPs gets distributed in liver, spleen, lungs, brain and kidneys, while majority were located in liver but these upon PEG-grafting rapidly taken up by peritoneal macrophages 31 . PLGA or its blend with β-cyclodextrin (PLGA-βCD), hydroxypropyl methylcellulose phthalate (PLGA-HP55) and Eudragit® RS (PLGA-ERS) are also exploited 75 . PLGA-βCD, PLGA-HP55 and star-branched form of PLGA exhibit burst release effect. While PLGA-ERS based NPs remains attached to intestinal epithelium and able to open TJs 75 . γPGAgraftedmesoporoussilicaNPs are pH-sensitive and possess much higher release rate at pH 5.5 comparing pH 7.4 72 .PLGA based NPs upon coating with chitosan exhibit improved mucoadhesion 59 . Co-encapsulating antacids (viz. magnesium hydroxide, magnesium carbonate or zinc carbonate) in PLGA NPs preserve the structure of macromolecules and protect them from GI tract degradation 76 . PLGA-based NPs targeting M cells might be more efficient for vaccine delivery that sustain release and deliver antigen directly to the immune cells and might achieve and have intrinsic adjuvanteffect on DCs 31, 57, 77 .PCL-ERS, and poly(allylamine) are alternatives for getting mucoadhesive NPs.
Dipalmitoyl-phosphatidylcholine (DPPC), egg, phosphatidylcholine, or phosphatidylinositol-cholesterol based LIP are used while DPPC offers protection of drug against degradation in GI tract and their entry in bloodstream, intact 45, 46 . Surface conjugation or coatings of LIP with mucin, PEG, wheat germ agglutinin (WGA), tomato lectin (TL) and Ulexeuropaeus agglutinin 1 (UA1) results targeting. Mucin-LIP and PEG-LIP results sustained release and provides protection against bile salts 1, 45, 46 . LIP-WGA is taken up by endocytosis, LIP-TL exhibits resistance to enzymatic action in the intestine and mucoadhesion, LIP-UA1 have targeting specificity to M cells of PPs 9, 45, 56, 57 . Co-encapsulation of permeation enhancers (e.g. sodium taurocholate, dimethyl palmitoylammoniopropanesulfonate) enhances bioavailability and paracellular translocation, through disrupting TJ 78 .
Poly(allylamine) are amphiphilic and protects macromolecules from degradation by pepsin, trypsin and chymotrypsin along with improvement of transcellular and paracellular transport while latter being via reversible disruption of TJs 28, 79 . PLA-Pluronic block copolymer based vesicles have ability to pass through cell membranes and attracted to small intestine 63 . Copolymer of pluronic-PAA and poloxamer minimise initial burst release of drug, in the acidic stomach, but releases drug, in a molecularly dispersed form, at pH five. Targeting and mucoadhesion property of these synergises efficiency and efficacy 39 . SLN ofcetylpalmitate sustain release while that of WGA-N-glutarylphosphatidylethanolamine exhibits protection against enzymatic degradation 11, 12, 43, 67, 80 14, 18 .
To avert drug release in GI tract, concentration of micelle to be above critical micelle concentration (CMC) and it shall expose to an ionic strength below their flocculation point 27, 81 .The inhibition of P-gp by pluronics is highest just below CMCwhereas that of PCL-PEG is above CMC 14, 18 . Micelles of poorly soluble drugs could be passively target by enhanced permeabilisation-retention effect 14 . Poly-ion complex micelle enhances transport across intestinal epithelial barrier 27, 28 . Pluronics, poloxamers, TPGS and PCL-PEG inhibit P-gp and enhance net drug transport through intestinal barrier 14, 18, 41, 63 .Some NPs enhances transcytosis through proteaseinhibition 82 . Multilayered NPs of alginate colocalises in the small intestinal mucosa. Amine-modified graft polyesters-chitosan NPs or thiolatedtrimethylchitosan NPs conserving degradation of macromolecules and facilitate their uptake, while latter had intrinsic adjuvanteffect on DCs 48, 77 .
Lipid-based systems (lipospheres, micelles, and LIP), prepared with several lipids including orexcluding emulsifying agents, well tolerated in living systems did not exhibit any cytotoxic effects, up to total of 2.5% lipid content.
LIPisadvantageous in terms of amphiphiliccharacter, biocompatibility, and ease of surface modification.SLNis innovative system having expectationfor more contributions, particularly,poor aqueous soluble macromolecules. Considering tolerability, surfactant of GRAS status used with preference, comparing lipids. Acylglycerols composed of fatty acids and lecithins mostly accepted as safe 19, 38 .
Surface charges or chemistry of nanocarriers seem to monitor their fate. Negatively charged one display higher transport rates referring near neutral, or positively charged 5, 64 . Fast-diffusing nanocarriers are achievable by coating their surface with PEG. This surface engineering modulates their mucoadhesive properties. Dense coating effectively minimises adhesive interactions of them with mucins, allowing penetration 21 .GI-residence time can be improved with cationic polymers or coating them with cationic groups or with thiol groups (binds to mucin) 21, 35. However, a balance between mucoadhesion and mucus penetration is important 5 .
Nanocarriers must be small enough to avoid significant steric inhibition by the fibre mesh and should avoid adhesion to mucin fibres; and to allow diffusion and uptake, but large enough to carry a favourable amount of macromolecules 48 . They being stable, non-toxic, bioabsorbable, non-thrombogenic, non-immunogenic, noninflammatory, avoid uptake by RES and have versatile applicability 1, 17, 20 . Cytotoxicity of nanovesicles is an essential product parameter of in vivo tolerance evaluation in humans and/or animals 17, 19, 38 .Their stability assessed involving approved method and accordingly shelf-life be assigned 39 .
Targeting of nanocarriers to globet cell 53, 54 PPs 9, 45, 56 DCs of PPs 57, 62 achieved with grafting of ligands. Optimisation of ligand density on their surface must allow tissue penetration and cellular uptake resulting in optimal therapeutic efficacy. Redressing issue of variation in M cells populations and receptors needed; those vary with species, anatomical location, age, sex and exogenous factors 1, 9, 10 .
In vitro models used for understanding fate of nanocarriers within intestinal epithelium is critical for their development. Combining both quantitative analysis method studying their transport and confocal microscopy, locating them, improve efficiency of study 39, 83 . Cellular tracking of them can be done with quantum dots technique that improves their visualization and dynamic colocalization microscopy 61, 83 . Quantitative and qualitative information such as diffusivity, viscoelasticity, pore size, velocity, directionality and transport mode of drug vectors can be determined from particle trajectories that reflect transport in mucus. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assays provide cytotoxic report of the nanocarriers 70 . Association of nanocarriers with DCs and their effect on their maturation determined flow-cytometrically 77 .
Novel NBODSM can be developed through 1 .
(i) Development of biocompatible polymers with tailored attributes for orally administered nanocarriers, (ii) Understanding the mechanisms of their cellular uptake, (iii)
Devising novel techniques for studying their fate including its components, and (iv)
Identifying ligands for their targeted delivery.
CONCLUSION
NBODSM will be a promising platform for orally delivering macromolecules. In vivo experimental results of animal models need to be interpreted and correlated with care, associated with existence of differences in anatomy and physiology of laboratory animals and humans. In order have successful NBODSM bioavailability of them to reach therapeutic level, with minimal inter and intra individual variation and toxicity had to be considered. Greater stability along with a financially feasible manufacturing process for mass production is prerequisite. Future will evidence utility of NBODSM in devising projected benefit in a cost-effective and sustainable way.
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